Tagged with CDMO

China In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft for a new BIOSECURE Act.   While the final version of the law, signed by President Donald Trump in December…

Taiwan Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By leveraging proprietary nanotechnology and antibody-drug conjugate platforms, the group is diversifying into injectables and considering the US market. Dr Cheng…

USA After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable supply. As CTO of Transcenta, he and his team have advanced continuous bioprocessing, delivering dramatic productivity improvements over traditional batch…

France The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics, vaccines, active pharmaceutical ingredients (APIs), and medtech. It offers potential investors a fully integrated value chain from early-stage R&D through…

Taiwan Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy. Under his leadership, Taiwan Bio advanced MSC and Tregmodalities, built infrastructure via its TDM model, and aims to make immunosuppressants…

USA Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought both CGT manufacturing and established GMP biosafety testing capabilities. Today, Minaris operates under private equity as two complementary businesses: Minaris…

USA Philip Macnabb serves as Chief Executive Officer of Curia, bringing 25 years of private equity-backed healthcare experience to his first venture into the CDMO sector. Joining in March 2023, Macnabb leads a globally diversified CDMO with 20 facilities spanning drug discovery through commercial manufacturing, serving predominantly biotech customers whilst maintaining…

Taiwan Dr David Chang discusses his vision for establishing the world’s premier cell and gene therapy contract development and manufacturing organisation in Taiwan. Drawing on more than 30 years of experience at Celgene, Roche, and Genentech, Dr Chang explains how Taiwan’s unique combination of technical talent, cost efficiency, and geopolitical positioning…

Taiwan Pei-Jiun Chen, CEO and President of Mycenax, outlines the company’s evolution into a focused, end-to-end biologics CDMO with deep roots in development excellence and GMP manufacturing. She highlights Japan as Mycenax’s core market, expansion into Europe, disciplined capacity growth, automation-driven productivity, and a niche, customer-centric model supporting complex biologics and…

USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…

Taiwan Sean Chang, CEO of Locus Cell, explains how his clinical CAR-T background led him to build a Taiwan-based CDMO for advanced cell therapies. The company is scaling Southeast Asia’s largest GMP facility, leveraging Taiwan’s manufacturing discipline, regulatory reforms and global partnerships to deliver high-quality, cost-competitive production bridging academic innovation and…

USA Alberto Santagostino, CEO of AGC Biologics, discusses how the company is positioning itself in an increasingly regionalized CDMO market, the strategic value of its global manufacturing footprint, and the role of technical expertise and long-term partnerships in supporting advanced biologics and cell and gene therapy programs. Santagostino goes on to…